Clinical trials: Mesothelin-positive
Lung Neoplasms
Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma
Background: Anetumab ravtansine is a new drug. It kills cancer cells that carry mesothelin. That is a protein on the surface of tumor cells in many types of tumors, including most lung cancers.
- Trial name
- NCT02839681
- Testing
- Anetumab Ravtansine, Blood test
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor
UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors
This is a single-arm, open-label, exploratory clinical study to evaluate the safety, tolerability and preliminary efficacy of UCLM802 (Anti-Mesothelin CAR-T) cell injection in patients with Mesothelin-positive advanced malignant…
- Trial name
- NCT05775666
- Testing
- UCLM802 Cell Injection
- Volunteers
- 87 people
- Sponsor
- Peking University
Neoplasms
Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment
To characterize the safety, tolerability, pharmacokinetics and immunogenicity of anetumab ravtansine in subjects with advanced solid cancers and with different degrees of hepatic or renal impairment
- Trial name
- NCT02696642
- Testing
- Anetumab ravtansine (BAY94-9343)
- Where
- 8 sites in France, Moldova
- Volunteers
- 54 people
- Sponsor
- Bayer
Advanced Solid Tumor
A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors
This is a multicenter, open-label Phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary clinical efficacy of HY05350 for injection in patients with MSLN-positive advanced…
- Trial name
- NCT07083323
- Testing
- HY05350 for injection
- Where
- China
- Volunteers
- 262 people, healthy volunteers welcome
- Sponsor
- Sichuan Huiyu Pharmaceutical Co., Ltd
Neoplasms, Pancreatic Neoplasms
Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
Background: LMB-100 is a man-made protein designed to kill cancer cells. LMB-100 targets a cancer marker called mesothelin. Mesothelin is found on the surface of many different tumors, including pancreatic cancer, but is made by…
- Trial name
- NCT02810418
- Testing
- LMB-100, Nab-Paclitaxel, Mesothelin Expression
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Thymoma, Stomach Neoplasms
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Background: Malignant mesothelioma is a malignancy arising from the mesothelial cells of the pleura, peritoneum, pericardium, or tunica vaginalis. Mesothelioma accounts for 0.10% of deaths annually in the United States.
- Conditions
- Thymoma, Stomach Neoplasms, Pancreatic Neoplasms, Mesothelioma
- Trial name
- NCT01950572
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer, Ovarian Cancer
αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologous mesothelin (MSLN)-targeted chimeric antigen receptor (MSLN-CAR) T cells secreting PD-1 nanobodies…
- Trial name
- NCT04503980
- Testing
- αPD1-MSLN-CAR T cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai Cell Therapy Group Co.,Ltd
Cancer, Mesothelin-positive
A Study of MORAb-009 in Patients With Solid Tumor
MORAb-009 is intravenously administered to patients with solid tumor once a week for 4 weeks as 1 cycle in order to investigate dose-limiting toxicity and estimate maximum tolerated dose.
- Trial name
- NCT01018784
- Testing
- MORAb-009
- Where
- Japan
- Volunteers
- 17 people
- Sponsor
- Eisai Co., Ltd.
Ovarian Cancer, Mesothelioma
An Open-label, Single-arm Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of KT032 Cell Injection in Patients With Mesothelin-positive Advanced Solid Tumors.
An Open-label, Single-arm Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of KT032 Cell Injection in Patients With Mesothelin-positive Advanced Solid Tumors.
- Conditions
- Ovarian Cancer, Mesothelioma, Colon Cancer
- Trial name
- NCT07420010
- Testing
- KT032(anti-MSLN chimeric antigen receptor autologous T cell injection)
- Volunteers
- 24 people
- Sponsor
- Weijia Fang, MD
Mesothelioma, Neoplasms
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Background: Mesothelioma is an aggressive cancer that grows in the linings of the body; this can include the membranes that line the heart, lungs, and internal organs.
- Conditions
- Mesothelioma, Neoplasms, Stomach Neoplasms, Pancreatic Neoplasms
- Trial name
- NCT06885697
- Testing
- cyclophosphamide, fludarabine, TNhYP218 CAR T Cells
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumor
PD-1 Antibody Expressing mesoCAR-T Cells for Mesothelin Positive Advanced Solid Tumor
This is a single-arm, open-label, one center clinical study, to determine the safety and efficacy of infusion of autologous T cells engineered to target mesothelin and express PD-1 antibodies in adult patients with advanced…
- Trial name
- PAEMCMPAST (NCT03615313)
- Testing
- PD-1 antibody expressing mesoCAR-T cells
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Cell Therapy Research Institute
Medical Oncology
Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors
Determine the safety, tolerability and maximum tolerated dose of anetumab ravtansine (BAY 94-9343) in combination with pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 in subjects with mesothelin-expressing predominantly epithelial…
- Trial name
- NCT02639091
- Testing
- BAY 94-9343, Pemetrexed, Cisplatin
- Where
- 6 sites in United States, Italy
- Volunteers
- 36 people
- Sponsor
- Bayer
Epithelial Ovarian Cancer, Triple Negative Breast Cancer
A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers
Study LCB-1801-001 is an open-label, Phase 1, dose escalation (Part A) and expansion (Part B), first-in-human clinical study of NI-1801 in patients with advanced, metastatic, or recurrent solid malignancies expressing mesothelin…
- Conditions
- Epithelial Ovarian Cancer, Triple Negative Breast Cancer, Non-squamous Non-small-cell Lung Cancer, Pancreatic Adenocarcinoma (ductal Adenocarcinoma)
- Trial name
- NCT05403554
- Testing
- Biological NI-1801, NI-1801 in combination with anti-PD1 (Pembrolizumab), NI-1801 in combination with paclitaxel
- Where
- 7 sites in France, Italy
- Volunteers
- 70 people
- Sponsor
- Light Chain Bioscience - Novimmune SA
Cancer
Safety and Efficacy of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors
This study is a single-center exploratory clinical trial. It is estimated that 9-24 subjects will be enrolled. The "3+3" dose escalation design is adopted.
- Trial name
- NCT05141253
- Testing
- RD133
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Tongji Hospital
Solid Tumor
An Exploratory Clinical Study of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors
This study is a single-center exploratory clinical trial. It is estimated that 9-24 subjects will be enrolled. The "3+3" dose escalation design is adopted.
- Trial name
- NCT05166070
- Testing
- RD133
- Where
- China
- Volunteers
- 24 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Malignant Pleural Mesotheliomas (Mpm), Malignant Pleural Effusions (Mpe)
Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin
Background: Cancers that spread into the thin tissue lining your lungs (pleura) cause serious illness. They often recur when removed.
- Conditions
- Malignant Pleural Mesotheliomas (Mpm), Malignant Pleural Effusions (Mpe), Epithelial Tumors, Malignant, Pleural Effusions, Malignant
- Trial name
- NCT05375825
- Testing
- Cytoreductive surgery, LMB-100, Immunohistochemical Assay for Mesothelin
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Medical Oncology
Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole
Characterize the safety, tolerability, ECG effects, pharmacokinetics and immunogenicity of anetumab ravtansine given as single agent and after inhibition of CYP3A4 and P-gp by concomitant administration of itraconazole in…
- Trial name
- NCT02824042
- Testing
- Anetumab ravtansine (BAY94-9343), Itraconazole
- Where
- 18 sites in United States, Australia and 4 more
- Volunteers
- 63 people
- Sponsor
- Bayer
Lung Cancer, Non-Small Cell Lung Cancer
LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Background: Over 230,000 new lung cancer cases are diagnosed every year in the United States (U.S.) About 80% of lung cancers are non- small cell lung cancer (NSCLC).
- Conditions
- Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma of Lung
- Trial name
- NCT04027946
- Testing
- LMB-100, pembrolizumab, Mesothelin Expression
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Mesothelin Positive, Stage III Non-Small Cell Lung Cancer AJCC v7
Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer
This phase I/II trial studies the best dose and side effects of anetumab ravtansine when given together with atezolizumab and how well they work in treating participants with non-small cell lung cancer that has spread to other…
- Conditions
- Mesothelin Positive, Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7
- Trial name
- NCT03455556
- Testing
- Anetumab Ravtansine, Atezolizumab, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- Mayo Clinic
Colorectal Cancer
Study of αPD1-MSLN-CAR T Cells to Evaluate the Safety, Tolerability, and Effectiveness for Patients With MSLN-positive Advanced Solid Tumors
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologous mesothelin (MSLN)-targeted chimeric antigen receptor (MSLN-CAR) T cells secreting PD-1 nanobodies…
- Trial name
- NCT05089266
- Testing
- CAR T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Cell Therapy Group Co.,Ltd